|
|
Article: Research and Markets: Strong Growth and Unfavorable Legislative Environment in the Generics Market Have Forced Pharmaceutical Companies to Reassess Strategies to Deliver Maximum Returns from Drug Portfolios.
- Article from:
- Business Wire
- Article date:
- February 21, 2005
CopyrightCOPYRIGHT 2005 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
DUBLIN, Ireland -- According to this report, a new breed of generics and R&D hybrid companies are emerging, which continue to threaten blockbuster drugs on one front while developing significant specialist R&D capabilities at the same time. 27% of branded pharmaceutical executives believe that over a quarter of the turnover of their top three brands are at risk from generic competition in the next five years and over 22% of executives say that their company does not have a defense strategy in place.
This report outlines key generics players and the strategies they are using to capture a larger market share of the drugs market. Today, pressure on the ...